View Author
patient cancer lymph prognostic tumor base model breast model dataset status breast cancer urokinase-type plasminogen activator analysis lymph node status curve plasminogen lymph node-positive patients activator level factor node-negative <.001 value lymph node-negative patients survival adjuvant treatment variable hormone-receptor status study cancer institute prognostic factors prognostic value adjuvant treatment inhibitor multivariable breast cancer patients table lymph node-negative grade urokinase-type number group result prognostic variables 10 years menopausal status analyses histologic grade hazard effect node-positive institute hormone-receptor assay prognostic score marker article 120 months tumor size january difference prognosis journal event ratio month urokinase plasminogen activator system addition method therapy likelihood ratio test relapse-free survival histologic score subgroups relapse-free laboratory tumor characteristics
4 Most Recent Publications
|
Methylated genes as new cancer biomarkers
(Article)
Duffy, M.J. Napieralski, R. Martens, J.W.M. Span, P.N. Spyratos, F. Sweep, F.C. Brünner, N. Foekens, J.A. Schmitt, M. |
2009-02-01
|
|
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers
(Article)
Sturgeon, C.M. Duffy, M.J. Haglund, C. Harbeck, N. Hayes, D.F. Holten-Andersen, M. Klee, G.G. Lamerz, R. Looijenga, L.H.J. Molina, R. Nielsen, H.J. Rittenhouse, H. Stenman, U-H. Semjonow, A. Shih, I-M. Sibley, P. Söleformos, G. Stephan, C. Sokoll, L. Hoffman, B.R. Diamandis, E.P. Lilja, H. Brünner, N. Chan, D.W. Babaian, R. Bast Jr, R.C. Dowell, B. Esteva, F.J |
2008-12-01
|
|
Protein kinase Cδ expression in breast cancer as measured by real-time PCR, western blotting and ELISA
(Article)
McKiernan, E. O'Brien, K. Sweep, F.C. Duffy, M.J. Grebenchtchikov, N. Geurts-Moespot, A. Sieuwerts, A.M. Martens, J.W.M. Magdolen, V. Evoy, D. McDermott, E. Crown, J. |
2008-11-04
|
|
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
(Article)
Look, M.P. Kueng, W. Kates, R. Magdelenat, H. Martin, P.M. Beex, L.V. Windbichler, G. Janicke, F. Spyratos, F. Peyrat , J.P. Ricolleau, G. Cufer, T. Klijn, J.G.M. Brunner, N. Meijer van Gelder, M.E. Bendahl, P.O. Ulm, K. Schmitt, M. Eppenberger-Castori, S. Sweep, C.G. Fiets, W.E. Duggan, C. Blankenstein, M.A. Broet, P. Borstnar, S. Daxenbichler, G. Foekens, J.A. O'Higgins, N. Duffy, M.J. Daver, A. Manders, P. Romain, S. Quillien, V. Harbeck, N. Eppenberger, U. Putten, W.L.J. van Ferno, M. Christensen, I.J. Lisboa, B.W. Thomssen, C. |
2002-01-16
|
